| Title: Regado Biosciences Raises $20 Million Series B |
Date: 8/30/2005
|
Regado Biosciences Raises $20 Million Series B
RTP-based Regado Biosciences, Inc. (www.regadobiosciences.com) has closed a $20 million Series B financing co-led by Domain Associates of Princeton, NJ, and Quaker BioVentures of Philadelphia, PA. Also participating in the round was The Aurora Funds of Durham, which provided seed funding for the company and led the Series A financing, as well as individual investors. In conjunction with the close of the financing, Jesse Treu, General Partner of Domain Associates and P. Sherrill Neff, Managing Partner of Quaker BioVentures, have joined the company's Board of Directors. The financing further validates Regado’s technology and will enable Regado to enter into a new phase of growth, according to company reports.
Regado is a spinout of the Department of Surgery at Duke University Medical Center. Regado's technology enables the rational design of drug- antidote pairs against any target accessible to the bloodstream. The company's lead product, REG1, is the first specific, direct acting, antidote-controlled anticoagulant for use in coronary revascularization procedures and for other acute coronary syndromes. |
